Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cysteamine for Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03883984
Recruitment Status : Recruiting
First Posted : March 21, 2019
Last Update Posted : March 21, 2019
Sponsor:
Information provided by (Responsible Party):
Children's Hospital Medical Center, Cincinnati

Brief Summary:
The purpose of this study is to see if a medicine called Cysteamine, given along with standard asthma care, will improve asthma symptoms and lung function.

Condition or disease Intervention/treatment Phase
Asthma Drug: Cysteamine Bitartrate Drug: Placebo Oral Tablet Phase 1

Detailed Description:

Asthma affects 25.7 million people in the US. Many people report symptoms despite taking high-doses of inhaled asthma medications. This difficult-to-treat group accounts for more than 50% of asthma related healthcare visits and hospitalizations. The purpose of this study is to see if a medicine called Cysteamine, given along with standard asthma care, will improve asthma symptoms and lung function.

This study is a double-blind, placebo-controlled, randomized trial of cysteamine. A placebo arm will be included to determine the comparative effectiveness of cysteamine in this population. Eligible participants will be assessed 1, 4 and 8 weeks post randomization and followed for an additional 4 weeks post treatment.

In order to enroll in this study, participants must be between the ages of 18-45 and have uncontrolled asthma.

This study will include 4 visits and weekly phone calls, and will be in the study for 3-4 months.

During the treatment period, participants will be placed in one of two treatment groups:

  • Cysteamine
  • Placebo

Participants will not be able to choose which group they are assigned. This assignment is random and by chance, much like flipping a coin. Participants will not know if they are receiving Cysteamine or placebo. Investigators will compare the study results between the participants of each group.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 1:1 randomized, double-blind, placebo-controlled trial
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Cysteamine for Asthma
Estimated Study Start Date : April 1, 2019
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: Cysteamine
Cysteamine Bitartrate plus standard asthma care
Drug: Cysteamine Bitartrate
Cysteamine bitartrate administered four times per day (QID) for 8 weeks. 125mg tablet QID.

Placebo Comparator: Placebo Oral Tablet
Placebo plus standard asthma care
Drug: Placebo Oral Tablet
Placebo administered for 8 weeks. 125mg tablet QID.




Primary Outcome Measures :
  1. Change in the Asthma Symptom Severity Score [ Time Frame: Baseline (Pre-Treatment), V1 (4 weeks), V2 (8 weeks), Study End (4 weeks post-treatment, Follow-up Phone Call) ]
    Asthma symptom severity score will be classified using the Expert Panel Report 3 (EPR-3) criteria for untreated asthma. The level of impairment is based on the most severe indication of the following criteria: 1. Symptoms, 2. Nighttime awakenings, 3. Short-Acting Beta Agonist (SABA) use for symptom control, 4. Interference with normal activity, and 5. Lung Function.


Secondary Outcome Measures :
  1. Number of Days with Albuterol Use Over Time [ Time Frame: Baseline (Pre-Treatment), V1 (4 weeks), V2 (8 weeks), Study End (4 weeks post-treatment, Follow-up Phone Call) ]
    Albuterol is a bronchodilator used as a rescue medication for treatment of asthma symptoms.

  2. Change in Inflammation in TH2 cells Over Time [ Time Frame: Baseline (Pre-Treatment), V1 (4 weeks), V2 (8 weeks, End Treatment) ]
    Inflammation as measured by T Helper Type 2 (TH2) cells in peripheral blood.

  3. Spirometry Measurement: Forced Expiratory Volume in 1 second (FEV1) Over Time [ Time Frame: Baseline (Pre-Treatment), V1 (4 weeks), V2 (8 weeks, End Treatment) ]
    FEV1 is the amount of air exhaled in 1 second during spirometry. This is used as a measurement of asthma severity.

  4. Peak Flow Measurement: Forced Expiratory Volume in 1 second (FEV1) Over Time [ Time Frame: Baseline (Pre-Treatment), V1 (4 weeks), V2 (8 weeks), Study End (4 weeks post-treatment, Follow-up Phone Call) ]
    FEV1 will be obtained by peak flow measurement. This will be used as a measurement in asthma severity.

  5. Peak Flow Measurement: Peak Expiratory Flow (PEF) Over Time [ Time Frame: Baseline (Pre-Treatment), V1 (4 weeks), V2 (8 weeks), Study End (4 weeks post-treatment, Follow-up Phone Call) ]
    PEF will be obtained by peak flow measurement. This will be used as a measurement in asthma severity.

  6. Change in Asthma Quality of Life Questionnaire (miniAQLQ) scores Over Time [ Time Frame: Baseline to Visit 2 (8 weeks) ]
    The miniAQLQ will be used to measure the impact that asthma has on participants quality of life. The miniAQLQ will ask questions in the following domains: symptoms, activity limitations, emotional function, and environmental stimuli. There are 15 questions, each with a 7-point scale. An answer of 1 on a question represents the greatest impairment possible and a 7 represents the least impairment. Individual questions are equally weighted. The overall miniAQLQ score is the mean of the responses to each of the 15 questions.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female
  • Age ≥ 18 years and ≤ 45 years
  • Provision of written informed consent
  • Asthma currently treated with moderate-high doses of Inhaled Corticosteroids (ICS) per the National Asthma Education and Prevention Program (NAEPP) guidelines by self-report
  • Evidence of hypersensitivity to environmental allergens, with at least one of the following:
  • Elevated serum IgE
  • Positive allergy skin prick testing to at least 1 allergen.
  • Evidence of allergic rhinitis by physical exam or by medical history.
  • Peripheral blood eosinophils ≥150 cells/µl obtained at screening visit.
  • Asthma Severity Score indicating Moderate to Severe Impairment based on EPR-3 classification guidelines
  • > 1 utilization for treatment of asthma exacerbation including prescription of oral or intravenous steroids (urgent care, emergency department visit, or hospitalization for asthma) in the past 12 months
  • Negative urine pregnancy test for females of child bearing potential and use of contraception throughout the study.

Exclusion Criteria:

  • Diagnosis of chronic lung disease other than asthma
  • Have received biologic therapy (e.g., anti-IgE, anti-IL-4, anti-IL-5) within 6 months of study entry.
  • Diagnosis of chronic disease other than asthma requiring daily steroids or immunosuppressive agents
  • History of a heart attack or severe chronic heart disease
  • Current smoking or previous history within 1 year
  • Transplant patient
  • IBD, Crohn's
  • History of ulcer, gastric esophageal reflux (GERD) or chronic peptic ulcer disease
  • Pregnant or planning to become pregnant
  • Breastfeeding
  • History of severe allergic or anaphylactic reactions to medications
  • Grade 2-4 Abnormal Laboratory Results (hemoglobin, WBC, lymphocytes, platelets, sodium, potassium, glucose, BUN, creatinine, calcium, albumin, total protein, alkaline phosphate, AST, ALT, and bilirubin), see table 7.4.1.2a and 7.4.1.2b.
  • Grade 3-4 Abnormal Eosinophils and Neutrophils, see table 7.4.1.2a.
  • Evidence of papilledema, or history of pseudotumor cerebri
  • History of persistent headaches
  • Allergic reaction to cysteamine or penicillamine
  • Serious medical condition that, in the opinion of the Study Investigator, would interfere with the ability of the patient to complete the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03883984


Contacts
Layout table for location contacts
Contact: Kristi Curtsinger, RN, BSN, BS 513-803-1651 kristi.curtsinger@cchmc.org

Locations
Layout table for location information
United States, Ohio
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Kristi Curtsinger, RN, BSN, BS    513-803-1651    kristi.curtsinger@cchmc.org   
Principal Investigator: Gurjit K Khurana Hershey, MD, PhD         
Sub-Investigator: Jocelyn Biagini Myers, PhD         
Sponsors and Collaborators
Children's Hospital Medical Center, Cincinnati
Investigators
Layout table for investigator information
Principal Investigator: Gurjit K Khurana Hershey, MD, PhD Children's Hospital Medical Center, Cincinnati

Layout table for additonal information
Responsible Party: Children's Hospital Medical Center, Cincinnati
ClinicalTrials.gov Identifier: NCT03883984     History of Changes
Other Study ID Numbers: Hershey-101
First Posted: March 21, 2019    Key Record Dates
Last Update Posted: March 21, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Lung Diseases, Obstructive
Lung Diseases
Bronchial Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Cysteamine
Cystine Depleting Agents
Molecular Mechanisms of Pharmacological Action